Spots Global Cancer Trial Database for A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
Official Title: A Phase 1 Dose Escalation and Expansion Study of OMP-305B83 in Subjects With Solid Tumors
Study ID: NCT02298387
Conditions
Interventions
Study Description
Brief Summary: This is an open-label Phase 1 dose escalation and expansion study of OMP-305B83 in subjects with previously treated solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.
Detailed Description: This is an open-label Phase 1 dose escalation and expansion study of OMP-305B83 in subjects with previously treated solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.
Keywords
Eligibility
Minimum Age: 21 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Oncology Research Associates, PLLC d/b/a Pinnacle Oncology Hematology, Scottsdale, Arizona, United States
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
University of Michigan Health System, Ann Arbor, Michigan, United States
University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Contact Details
Name: David Smith, MD,FACP
Affiliation: University of Michigan
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
